Glycoprotein therapeutic - Boston Therapeutics

Drug Profile

Glycoprotein therapeutic - Boston Therapeutics

Alternative Names: Ipoxyn

Latest Information Update: 07 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boston Therapeutics
  • Class Glycoproteins
  • Mechanism of Action Oxygen carriers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Anaemia; Cardiovascular disorders; Peripheral ischaemia

Most Recent Events

  • 07 Jun 2017 Boston Therapeutics is seeking partners for funding the development of glycoprotein therapeutic as of 28 Mar 2017 .
  • 28 Mar 2017 Suspended - Preclinical for Peripheral ischaemia, Cardiovascular disorders and Anaemia in USA until Boston Therapeutics can secure funds for the compound (IV)
  • 30 May 2014 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top